Emerging Markets Regulatory Tracker: China Biosimilar Guidance Finalized
This article was originally published in PharmAsia News
Executive Summary
China’s FDA has now issued the final version of its guidance on biosimilars that was issued for comment last year, taking into account some of the feedback it received.